Moleculin Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Moleculin Biotech's estimated annual revenue is currently $5.4M per year.
- Moleculin Biotech's estimated revenue per employee is $201,000
Employee Data
- Moleculin Biotech has 27 Employees.
- Moleculin Biotech grew their employee count by 29% last year.
Moleculin Biotech's People
Name | Title | Email/Phone |
---|---|---|
1 | CMO - Part-time | Reveal Email/Phone |
2 | VP, Drug Development Portfolio Management | Reveal Email/Phone |
3 | VP, Clinical Operations | Reveal Email/Phone |
4 | Associate Director Clinical Operations | Reveal Email/Phone |
5 | Associate Director Operations | Reveal Email/Phone |
6 | Chief Financial Officer and EVP | Reveal Email/Phone |
7 | Chief Medical Officer – New Products | Reveal Email/Phone |
8 | Chief Science Officer | Reveal Email/Phone |
9 | Senior Program Manager | Reveal Email/Phone |
10 | Assistant Controller | Reveal Email/Phone |
Moleculin Biotech Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $26.7M | 133 | 20% | N/A | N/A |
#2 | $13.5M | 67 | 6% | N/A | N/A |
#3 | $16.1M | 80 | -2% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $10.1M | 50 | 6% | N/A | N/A |
#6 | $119.4M | 594 | 27% | N/A | N/A |
#7 | $22.9M | 114 | 8% | N/A | N/A |
#8 | $92.9M | 462 | 8% | N/A | N/A |
#9 | $11.3M | 56 | -8% | N/A | N/A |
#10 | $7M | 35 | 6% | N/A | N/A |
What Is Moleculin Biotech?
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical-stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer, and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.
keywords:N/AN/A
Total Funding
27
Number of Employees
$5.4M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Moleculin Biotech News
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly...
In the Biotechnology industry, which ranks 136 out of 146 industries, Moleculin Biotech Inc ranks higher than 12% of stocks.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.1M | 27 | -37% | $289.6M |
#2 | $3.4M | 27 | 0% | N/A |
#3 | $2.7M | 27 | N/A | N/A |
#4 | $2.7M | 27 | N/A | N/A |
#5 | $2.7M | 27 | N/A | N/A |